Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00966693 · OUTCOME

Time to Next Therapy

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma · Source last updated 2020-11-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 4.5 years

What was measured

Estimated using the method of Kaplan and Meier.

Groups in this outcome

RTD (Cohort 1, Phase 1)

Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle

RTD (Cohort 2, Phase 1)

Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \*21 days+ 7 days rest and reevaluation=28 day cycle

RTD (Cohort 3, Phase 1)

Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle

RTD (Cohort 2, Phase 2)

Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \*21 days+ 7 days rest and reevaluation=28 day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
RTD (Cohort 1, Phase 1)3
RTD (Cohort 2, Phase 1)3
RTD (Cohort 3, Phase 1)9
RTD (Cohort 2, Phase 2)49

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
RTD (Cohort 1, Phase 1)52.4Not reported1.94NAinsufficient number of participants with events
RTD (Cohort 2, Phase 1)14.3Not reported5.19NAinsufficient number of participants with events
RTD (Cohort 3, Phase 1)10.5Not reported4.96NAinsufficient number of participants with events
RTD (Cohort 2, Phase 2)6.47Not reported4.14NAinsufficient number of participants with events
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        insufficient number of participants with events
        group Id
        OG000
        lower Limit
        1.94
        upper Limit
        NA
        value
        52.4
      2. comment
        insufficient number of participants with events
        group Id
        OG001
        lower Limit
        5.19
        upper Limit
        NA
        value
        14.3
      3. comment
        insufficient number of participants with events
        group Id
        OG002
        lower Limit
        4.96
        upper Limit
        NA
        value
        10.5
      4. comment
        insufficient number of participants with events
        group Id
        OG003
        lower Limit
        4.14
        upper Limit
        NA
        value
        6.47
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      9
    4. group Id
      OG003
      value
      49
    units
    Participants
description
Estimated using the method of Kaplan and Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle
    id
    OG000
    title
    RTD (Cohort 1, Phase 1)
  2. description
    Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \*21 days+ 7 days rest and reevaluation=28 day cycle
    id
    OG001
    title
    RTD (Cohort 2, Phase 1)
  3. description
    Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle
    id
    OG002
    title
    RTD (Cohort 3, Phase 1)
  4. description
    Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \*21 days+ 7 days rest and reevaluation=28 day cycle
    id
    OG003
    title
    RTD (Cohort 2, Phase 2)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 4.5 years
title
Time to Next Therapy
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice